As GSDMB is highly expressed in most HER2 breast cancers and leads to resistance to anti-HER2 treatments, researchers have developed a nanocapsule loaded with an anti-GSDMB antibody and targeted GSDMB-overexpressing cancer cells. Here, GSDMB is linked to breast cancer.